Loading...
•
Dec 31, 2025
Recursion Pharmaceuticals Q4 2025 Earnings Report
Recursion reported higher fourth quarter revenue driven by collaboration milestones, reduced net loss year over year, and a strengthened cash position.
Key Takeaways
For Q4 2025, Recursion generated 35537000 in total revenue, primarily from collaboration agreements, compared to 4546000 in Q4 2024. Net loss narrowed to 108124000 from 178905000 in the prior year quarter. The company ended the quarter with 753921000 in cash, cash equivalents and restricted cash.
Total revenue increased to 35537000 from 4546000 year over year.
Net loss improved to 108124000 compared to 178905000 in Q4 2024.
Research and development expenses were 95940000 in the quarter.
Cash, cash equivalents and restricted cash totaled 753921000 at quarter end.
Revenue by Segment
Forward Guidance
Management expects cash runway into early 2028 without additional financing and 2026 cash operating expense, excluding partnership inflows and transaction costs, to be less than 390000000.
Positive Outlook
- Cash runway expected into early 2028 without additional financing.
- 2026 cash operating expense expected to be less than 390000000.
- Continued milestone potential from Sanofi collaboration.
- Ongoing partnered discovery opportunities with Roche and Genentech.
- Operational efficiencies achieved in 2025.
Challenges Ahead
- Net loss of 108124000 in Q4 2025.
- High quarterly R&D expenses of 95940000.
- Continued dependence on collaboration milestone timing.
- Operating loss of 108335000 in the quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...